News

Each unit consists of (i) one share of Pieris’ common stock or non-voting series A convertible preferred stock convertible into one share of common stock, (ii) 0.40 warrants

Over three years, Adimab will use its proprietary, yeast-based discovery platform to generate IgGs or bispecifics for development as therapeutic products for multiple targets chosen by Innovent. Innovent

Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer. Dr. Steve Quay, President

The collaboration will help support multiple Phase 1 and 2 clinical trials testing Opdivo as monotherapy, in combination with Yervoy, or in regimens with other agents, radiation or

The double-blind, placebo-controlled study randomized 153 patients into four treatment arms. All participants were on statin therapy and had LDL-C levels between 70 and 190 mg/dL. At baseline,

The 395-patient study assessed the safety and efficacy of 5 mg and 10 mg of tofacitinib administered twice daily in adult patients with active psoriatic arthritis (PsA) who

Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop multiple bispecific antibodies for the Chinese market, including the

Charles River will be a key partner as Moderna continues to grow and advance its pipeline spanning multiple drug modalities and therapeutic areas, conducting nonclinical activities to progress

The acquisition includes Sun Pharma’s oral solid dosage manufacturing facilities in Philadelphia, PA, and Aurora, IL and 15 related pharmaceutical products (the "Acquired Products"). Terms of the transaction